Biocon Biologics’ (BBL) revenues for Q1 FY24 saw an over 100% year-on-year growth, driven by the consolidation of the biosimilars business acquired from Viatris, as well as higher sales of commercialized products that is reflected in their market share gains in U.S. & Europe. The robust performance this quarter has given Biocon Biologics the impetus … Continue reading Consolidation of acquired business fuels Biocon Biologics’ growth trajectory
Delivering on ‘Power of One’; Biocon Biologics starts FY24 on a Strong Footing with 2-fold Revenue Jump in Q1
Biocon Biologics Limited (BBL) got off to a promising start to FY24 with an over two-fold increase in first-quarter revenues, truly reflecting the “Power of One” derived from the Company's transformative acquisition of the global biosimilars of its long-term partner Viatris. Driven by market share gains for its commercialized biosimilars in key markets and the … Continue reading Delivering on ‘Power of One’; Biocon Biologics starts FY24 on a Strong Footing with 2-fold Revenue Jump in Q1
The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw
Biocon Biologics on Monday announced a transformational deal to acquire partner Viatris’ global biosimilars business for up to USD 3.335 billion in cash and stock. The acquisition of the business, which is estimated to generate revenues of USD 1 billion next year, will create a unique, fully integrated global biosimilars enterprise. Kiran Mazumdar-Shaw, Executive Chairperson, … Continue reading The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw
Biocon’s Landmark Achievement of First USFDA approval for Biosimilar Trastuzumab applauded by all including the Media
First Biosimilar Trastuzumab approved in the US
A Blog by Biocon 